ライフサイエンスコーパス: in the intention-to-treat population

1 In the intention-to-treat population, 29 of 42 patients who r

2 In the intention-to-treat population, patients receiving atez

3 In the intention-to-treat population, the primary end point o

4 ttee using Response Evaluation Criteria in Solid Tumors 1.1 in the intention-to-treat population, assessed every 6 weeks

5 ab vedotin and 65 to physician's choice), with 128 analysed in the intention-to-treat population (64 in each group).

6 me from randomisation until death from any cause), analysed in the intention-to-treat population.

7 angina, and hospital admission for heart failure, analysed in the intention-to-treat population (all participants random

8 Primary outcomes were OS (analysed in the intention-to-treat population) and adverse events (ana

9 safety and tolerability of the treatment regimen, analysed in the intention-to-treat population.

10 The primary endpoint was overall survival analysed in the intention-to-treat population.

11 Efficacy was analysed in the intention-to-treat population; safety was analysed in

12 These endpoints were analysed in the intention-to-treat population.

13 We did the analysis in the intention-to-treat population.

14 Data were analysed with descriptive statistics and in the intention-to-treat population.

15 Primary endpoint is disease-free survival, and analyses are in the intention-to-treat population.

16 ived at least one dose of lorlatinib; efficacy was assessed in the intention-to-treat population (patients who received a

17 The primary endpoint (overall survival) was assessed in the intention-to-treat population.

18 Efficacy was assessed in the intention-to-treat populations and safety in patients

19 n-free survival assessed by an independent review committee in the intention-to-treat population.

20 im analysis met the prespecified futility stopping criteria in the intention-to-treat population.

21 randomisation and death from any cause or the censor date) in the intention-to-treat population.

22 154 (60%) of 257 patients died in the intention-to-treat population: 74 (57%) of 129 patient

23 The primary efficacy analysis was done in the intention-to-treat population and was stratified into

24 The primary efficacy analysis was done in the intention-to-treat population.

25 The primary analysis was done in the intention-to-treat population.

26 Primary and safety analyses were done in the intention-to-treat population.

27 Efficacy analyses were done in the intention-to-treat population.

28 overall survival, and primary and safety analyses were done in the intention-to-treat population.

29 hological complete response (ypT0/is, ypN0), between groups in the intention-to-treat population (two-sided assessment),

30 23, 2015, 6522 patients were randomly assigned and included in the intention-to-treat population, 3272 assigned to acarbo

31 atients underwent randomization, of whom 1435 were included in the intention-to-treat population.

32 remission from depression (PHQ-9 score of <10) at 3 months in the intention-to-treat population, assessed by masked fiel

33 the ataluren group and those in the placebo group, neither in the intention-to-treat population nor in the prespecified

34 All patients in the intention-to-treat population who initiated protocol t

35 Safety assessment was done in all patients in the intention-to-treat population.

36 The primary endpoint was the proportion of patients in the intention-to-treat population achieving an objective g

37 in progression-free survival between simtuzumab and placebo in the intention-to-treat population (median progression free

38 (4% margin) of the study regimen versus the control regimen in the intention-to-treat population.

39 Here, we report the results in the intention-to-treat population of the first phase of th

40 rogression-free survival assessed by blinded central review in the intention-to-treat population.

41 The primary outcome was the AQLQ score in the intention-to-treat population at 12 months.

42 The co-primary endpoints were progression-free survival in the intention-to-treat population and progression-free sur

43 Median progression-free survival in the intention-to-treat population was 6.2 months (95% CI 3

44 The primary endpoint was overall survival in the intention-to-treat population and safety was assessed

45 Median overall survival in the intention-to-treat population did not differ between t

46 tor-assessed progression-free survival and overall survival in the intention-to-treat population.

47 fections, treatment-related mortality, and overall survival in the intention-to-treat population.

48 The primary endpoint was overall survival in the intention-to-treat population.

49 Ten days after therapy in the intention-to-treat population, the cure rate among par

50 ion-free survival, overall survival, and pulmonary toxicity in the intention-to-treat population.